The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant chemotherapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in patients with locally advanced (LA) triple-negative breast cancer (TNBC).
Mona Frolova
No relevant relationships to disclose
Marina Skrypnikova
No relevant relationships to disclose
Ekaterina Ignatova
No relevant relationships to disclose
Alexander Petrovsky
No relevant relationships to disclose
Marina Stenina
No relevant relationships to disclose
Oxana Ivankina
No relevant relationships to disclose
Yana Vishnevskaja
No relevant relationships to disclose
Sergei Tjulandin
No relevant relationships to disclose